AI technology is increasingly being applied in the field of pharmaceutical research and development, continuously reshaping the landscape of medical innovation. We are pleased to announce that Mindrank AI Ltd., a new member specializing in AI-driven drug discovery, has officially joined the Roche China Accelerator. Let us work together to advance more efficient and precise drug development pathways.
DreaMed Pharma is a clinical-stage, AI-driven drug discovery and development company, composed of over 40 scientists, including biopharmaceutical experts and global AI competition champions. The team has extensive industry experience and a proven track record in drug discovery and AI-driven technological innovation. By leveraging AI technology, the company aims to enhance the efficiency and success rate of new drug development, helping more patients regain their health.
Dr. Zhangming Niu, Founder & CEO of Dharmaetix, said: "We are thrilled to join Roche China Accelerator and establish closer connections with globally leading biopharmaceutical technology companies. We look forward to leveraging Roche's extensive expertise in early-stage research, clinical development, and global resources to explore closer collaboration in the 'AI-driven design, clinical validation, and commercialization' pipeline of drug discovery, bringing innovative therapies to benefit the public."
Drenai leverages its self-developed, industrial-grade, all-in-one AI-driven platform for innovative drug discovery, encompassing a knowledge graph-based data mining platform, a protein dynamics simulation and structure prediction platform, and an all-in-one AI drug design platform, focusing on tackling "undruggable" molecular targets and accelerating the new drug discovery process.
Roche China Accelerator closely monitors the latest trends in technological advancements and actively embraces the wave of AI applications in drug discovery. We believe AI is reshaping the path of drug discovery and will become a key driving force in transforming the pharmaceutical industry. Roche China Accelerator will continue to bring in cutting-edge projects empowered by AI. We look forward to collaborating with more innovators in exploring the unknown, seizing the opportunities of future pharmaceutical transformation, and delivering more groundbreaking therapies for patients.